ReviewDer Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen2020
[Indications and results of radioiodine treatment of differentiated thyroid cancer].
Review in Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
- Hemodialysis-associated radioactive waste management in [Journal of applied clinical medical physics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMalignant tumors of the thyroid gland are the most frequent malignant endocrine neoplasms, comprising approximately 1% of all malignant tumors. In recent years there has been a clear rise in the incidence of differentiated thyroid carcinomas (DTC), especially small papillary carcinomas.
objectiveIndications for and results of radioiodine treatment (RAI) of DTC. MATERIAL AND
methodsA review of the current literature and guidelines of RAI in DTC was carried out.
resultsThe use of RAI is the most important adjuvant treatment option for DTC and is generally well-tolerated.
conclusionDue to the combination of surgery and RAI the DTC has a very good prognosis compared with other cancers, with an average survival rate of more than 90%.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.